Antibodies to human il-1beta

Abstract

An IL-1β binding molecule, in particular an antibody to human IL-1β, especially a human antibody to human IL-1β is provided, wherein the CDRs of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteoporosis and other inflammatory arthritides.

1 - 12 . (canceled) 
     
     
         13 . A polynucleotide construct that encodes an immunoglobulin heavy chain or fragment thereof of an IL-1β binding molecule, wherein said immunoglobulin heavy chain comprises a heavy chain constant domain or fragment thereof and a heavy chain variable domain or fragment thereof, and wherein said heavy chain variable domain comprises framework regions and a first region consisting of amino acids 31 to 35 of SEQ ID NO:1, a second region consisting of amino acids 50 to 66 of SEQ ID NO:1, and a third region consisting of amino acids 99 to 107 of SEQ ID NO:1. 
     
     
         14 . A polynucleotide construct that encodes an immunoglobulin light chain or fragment thereof IL-1β binding molecule, wherein said immunoglobulin light chain comprises a light chain constant domain or fragment thereof and a light chain variable domain or fragment thereof, and wherein said light chain variable domain comprises framework regions and a first region consisting of amino acids 24 to 34 of SEQ ID NO:2, a second region consisting of amino acids 50 to 56 of SEQ ID NO:2 and a third region consisting of amino acids 89 to 97 of SEQ ID NO:2. 
     
     
         15 . A polynucleotide encoding an isolated IL-1β binding molecule comprising a heavy chain variable domain comprising SEQ ID NO:1 or a light chain variable domain comprising SEQ ID NO:2. 
     
     
         16 . A polynucleotide encoding an isolated IL-1β binding molecule comprising the three CDRs of SEQ ID NO:1 or the three CDRs of SEQ ID NO:2. 
     
     
         17 . A polynucleotide encoding an isolated IL-1β binding molecule comprising SEQ ID NO:5. SEQ ID NO:6 and SEQ ID NO:7 or SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10. 
     
     
         18 . An expression vector able to replicate in a prokaryotic or eukaryotic cell which comprises the construct according to  claim 13 . 
     
     
         19 . An expression vector able to replicate in a prokaryotic or eukaryotic cell which comprises the construct according to  claim 14 . 
     
     
         20 . An expression vector able to replicate in a prokaryotic or eukaryotic cell which comprises the polynucleotide according to  claim 15 . 
     
     
         21 . An expression vector able to replicate in a prokaryotic or eukaryotic cell which comprises the polynucleotide according to  claim 16 . 
     
     
         22 . An expression vector able to replicate in a prokaryotic or eukaryotic cell which comprises the polynucleotide according to  claim 17 . 
     
     
         23 . A prokaryotic or eukaryotic host cell comprising the construct according to  claim 13 . 
     
     
         24 . A prokaryotic or eukaryotic host cell comprising the construct according to  claim 14 . 
     
     
         25 . A prokaryotic or eukaryotic host cell comprising the polynucleotide according to  claim 15 . 
     
     
         26 . A prokaryotic or eukaryotic host cell comprising the polynucleotide according to  claim 16 . 
     
     
         27 . A prokaryotic or eukaryotic host cell comprising the polynucleotide according to  claim 17 . 
     
     
         28 . A process for the production of an IL-1β binding molecule which comprises (i) culturing the host cell of  claim 23  to yield a cell culture and (ii) recovering the IL-1β binding molecule from said cell culture. 
     
     
         29 . A process for the production of an IL-1β binding molecule which comprises (i) culturing the host cell of  claim 24  to yield a cell culture and (ii) recovering the IL-1β binding molecule from said cell culture. 
     
     
         30 . A process for the production of an IL-1β binding molecule which comprises (i) culturing the host cell of  claim 25  to yield a cell culture and (ii) recovering the IL-1β binding molecule from said cell culture. 
     
     
         31 . A process for the production of an IL-1β binding molecule which comprises (i) culturing the host cell of  claim 26  to yield a cell culture and (ii) recovering the IL-1β binding molecule from said cell culture. 
     
     
         32 . A process for the production of an IL-1β binding molecule which comprises (i) culturing the host cell of  claim 27  to yield a cell culture and (ii) recovering the IL-1β binding molecule from said cell culture. 
     
     
         33 . A method for treating an IL-1β mediated disease or disorder or an inflammatory disease or disorder in a subject in need thereof comprising administering to the subject an effective amount of an IL-1β binding molecule comprising a heavy chain variable domain comprising SEQ ID NO:1. 
     
     
         34 . A method for treating an IL-1β mediated disease or disorder or an inflammatory disease or disorder in a subject in need thereof comprising administering to the subject an effective amount of an IL-1β binding molecule comprising a light chain variable domain comprising SEQ ID NO:2. 
     
     
         35 . The method of  claim 33 , wherein the IL-1β binding molecule further comprises a light chain variable domain comprising SEQ ID NO:2. 
     
     
         36 . The method of  claim 34 , wherein the IL-1β binding molecule further comprises a heavy chain variable domain comprising SEQ ID NO:1. 
     
     
         37 . A method for treating an IL-1β mediated disease or disorder or an inflammatory disease or disorder in a subject in need thereof comprising administering to the subject an effective amount of an isolated IL-1β binding molecule comprising a heavy chain variable domain comprising SEQ ID NO:1 and a light chain variable domain comprising SEQ ID NO:2. 
     
     
         38 . A method for treating an IL-1β mediated disease or disorder or an inflammatory disease or disorder in a subject in need thereof comprising administering to the subject an effective amount of an isolated IL-1β binding molecule comprising a heavy chain variable domain comprising the three CDRs of SEQ ID NO:1 and a light chain variable domain comprising the three CDRs of SEQ ID NO:2. 
     
     
         39 - 40 . (canceled) 
     
     
         41 . A method for treating an IL-1β mediated disease or disorder or an inflammatory disease or disorder in a subject in need thereof comprising administering to the subject an effective amount of an isolated IL-1β binding molecule that is capable of inhibiting the binding of IL-1β to the IL-1β receptor to the same extent as an IL-1β binding molecule comprising a heavy chain variable domain comprising SEQ ID NO:1 and a light chain variable domain comprising SEQ ID NO:2. 
     
     
         42 . A method for treating an IL-1β mediated disease or disorder or an inflammatory disease or disorder in a subject in need thereof comprising administering to the subject an effective amount of an isolated IL-1β binding molecule that is capable of inhibiting the binding of IL-1β to the IL-1β receptor to the same extent as an IL-1β binding molecule comprising a heavy chain variable domain comprising the three CDRs of SEQ ID NO:1 and a light chain variable domain comprising the three CDRs of SEQ ID NO:2. 
     
     
         43 . The method according to  claim 38 , wherein said IL-1β binding molecule is a human antibody. 
     
     
         44 . A method for treating an IL-1β mediated disease or disorder or an inflammatory disease or disorder in a subject in need thereof comprising administering to the subject an effective amount of an IL-1β binding molecule encoded by the polynucleotide of  claim 15 . 
     
     
         45 . A method for treating an IL-1β mediated disease or disorder or an inflammatory disease or disorder in a subject in need thereof comprising administering to the subject an effective amount of an IL-1β binding molecule encoded by the polynucleotide of  claim 16 . 
     
     
         46 . A method for treating an IL-1β mediated disease or disorder or an inflammatory disease or disorder in a subject in need thereof comprising administering to the subject an effective amount of an IL-1β binding molecule encoded by the polynucleotide of  claim 17 . 
     
     
         47 . The method according to  claim 46 , wherein said IL-1β binding molecule is a human antibody. 
     
     
         48 . A method for modulating IL-1β in a subject, comprising administering to the subject an isolated IL-1β binding molecule encoded by the polynucleotide of  claim 15 . 
     
     
         49 . A method for modulating IL-1β in a subject, comprising administering to the subject an isolated IL-1β binding molecule encoded by the polynucleotide of  claim 16 . 
     
     
         50 . A method for modulating IL-1β in a subject, comprising administering to the subject an isolated IL-1β binding molecule encoded by the polynucleotide of  claim 17 . 
     
     
         51 . A method for binding IL-1β in a subject, comprising administering to the subject an isolated IL-1β binding molecule encoded by the polynucleotide of  claim 15 . 
     
     
         52 . A method for binding IL-1β in a subject, comprising administering to the subject an isolated IL-1β binding molecule encoded by the polynucleotide of  claim 16 . 
     
     
         53 . A method for binding IL-1β in a subject, comprising administering to the subject an isolated IL-1β binding molecule encoded by the polynucleotide of  claim 17 . 
     
     
         54 . A method for administering an isolated IL-1β binding molecule to a subject, comprising administering to the subject a pharmaceutical composition comprising an isolated IL-1β binding molecule encoded by the polynucleotide of  claim 15 . 
     
     
         55 . A method for administering an isolated IL-1β binding molecule to a subject, comprising administering to the subject a pharmaceutical composition comprising an isolated IL-1β binding molecule encoded by the polynucleotide of  claim 16 . 
     
     
         56 . A method for administering an isolated IL-1β binding molecule to a subject, comprising administering to the subject a pharmaceutical composition comprising an isolated IL-1β binding molecule encoded by the polynucleotide of  claim 17 . 
     
     
         57 . An isolated IL-1β binding molecule that is capable of inhibiting the binding of IL-1β to the IL-1β receptor to the same extent as an IL-1β binding molecule encoded by the polynucleotide of  claim 15 . 
     
     
         58 . An isolated IL-1β binding molecule that is capable of inhibiting the binding of IL-1β to the IL-1β receptor to the same extent as an IL-1β binding molecule encoded by the polynucleotide of  claim 16 . 
     
     
         59 . An isolated IL-1β binding molecule that is capable of inhibiting the binding of IL-1β to the IL-1β receptor to the same extent as an IL-1β binding molecule encoded by the polynucleotide of  claim 17 .